Author: McKinley Corbley / Source: Good News Network
This exciting new drug treatment could help to extend the lifespans of women suffering from one of the world’s worst cancer survival rates.
Ever after undergoing chemotherapy and surgery, 70% of ovarian cancer patients suffer relapses within three years of treatment – and only 35% are still alive ten years after their initial diagnosis.
Once the cancer returns, it is considered terminal.According to these “unprecedented” trial results, however, a new drug called olaparib has dramatically increased the lifespan and survival rates of ovarian cancer patients.
The drug was given to women who had successfully eliminated all or part of the cancer by undergoing chemotherapy. Three years after the women were started on the drug in 2013, researchers found that the…
The post Ovarian Cancer ‘Breakthrough’ Drug Prevents Disease Returning for Years appeared first on FeedBox.